Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf
Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary duties owed to the company.
If you have held Akero Therapeutics, Inc. (NASDAQ: AKRO) shares since prior to September 13, 2022, you can seek corporate reforms, the return of money back to the company, and a court approved monetary award at no cost to you whatsoever. You are encouraged to learn more about the investigation and your rights by visiting https://grabarlaw.com/the-latest/akero-shareholder-investigation/. You can also contact Joshua Grabar at [email protected] or call 267-507-6085.
WHY: A recently filed underlying securities fraud class action Complaint alleges that Akero Therapeutics, via certain of its officers and directors, made false and/or misleading statements and/or failed to disclose to the investing public that: (i) approximately 20% of the patients enrolled in its SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline; (ii) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH; (iii) the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints; (iv) Akero had introduced a confounding factor into the SYMMETRY study's design, materially influencing the study's potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not ruled out potential causes of each patient's cirrhosis other than NASH; and (vi) consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhotics.
WHAT YOU CAN DO NOW: Current Akero shareholders who have held Akero shares since on or before September 13, 2022, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever.
If you would like to learn more about this matter, please visit https://grabarlaw.com/the-latest/akero-shareholder-investigation/, contact Joshua Grabar at [email protected] or call us at 267-507-6085. $AKRO #Akero
Driven Brands Holdings, Inc. (NASDAQ: DRVN) Class Action Survives Motion to Dismiss:
A securities fraud class action complaint against Driven Brands Holdings, Inc. (NASDAQ: DRVN) has survived defendants, attempts to dismiss the complaint. Grabar Law Office is now investigating claims on behalf of long-term Driven Brands shareholders. The investigation concerns whether certain officers of the company have breached their fiduciary duties they owed to the company.
If you have held Driven Brands (NASDAQ: DRVN) shares continuously since prior to October 27, 2021, you can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you. Visit https://grabarlaw.com/the-latest/driven-brands-shareholder-investigation/ or contact Joshua H. Grabar at [email protected] or call 267-507-6085 to learn more.
WHY: An underlying securities fraud class action complaint alleges that Driven Brands, through certain of its officers and directors, made numerous materially false and misleading statements and omissions pertaining to: (i) Driven Brands' ability to efficiently and effectively integrate a high volume of acquired businesses, including statements related to the status of integrating its U.S. auto glass businesses; and (ii) the performance and competitive position of Driven Brands' car wash business segment.
On February 20, 2025, a Federal Court determined that the allegations in the plaintiff's underlying securities fraud class action complaint were adequately pleaded to survive defendants attempts to dismiss the complaint.
WHAT TO DO NOW: If you are a current Driven Brands shareholder who has held Driven Brands shares since prior to October 27, 2021, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/driven-brands-shareholder-investigation/, contact Joshua H. Grabar at [email protected] or call 267-507-6085. $DRVN #DrivenBrands
Integra LifeSciences Holdings Corp. (NASDAQ: IART):
Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) breached their fiduciary duties owed to the Company.
Current Integra LifeSciences Holdings Corp. (NASDAQ: IART) shareholders who have held the stock since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them. Learn more or join at: https://grabarlaw.com/the-latest/intrga-lifesciences-shareholder-investigation/. Contact Joshua H. Grabar at [email protected], or call 267-507-6085.
WHY: An underlying securities fraud class action complaint alleges that Integra, via certain of his officers and directors, repeatedly touted that it was on track to grow SurgiMend's market by obtaining FDA approval for use in post-mastectomy reconstruction, yet on May 23, 2023, the Company was forced to announce a 'recall' of all products manufactured at its Boston Facility between March 1, 2018 and May 22, 2023. Integra LifeSciences explained that it had determined that the Boston Facility deviated from good manufacturing practices in testing for bacterial endotoxin and allowed the release of products with unsafe levels of endotoxins. As a result of the recall and manufacturing shutdown, the Company revised its guidance for the second quarter of 2023, lowering its revenue expectations by and disclosed that it expected to take a $22 million impairment due to the inventory write-off.
WHAT TO DO NOW: Current Integra LifeSciences shareholders who have held Integra LifeSciences shares since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.
If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/intrga-lifesciences-shareholder-investigation/, contact Joshua H. Grabar at [email protected], or call us at 267-507-6085. $IART #IntegraLifeSciences
Kyverna Therapeutics, Inc. (NASDAQ: KYTX):
Grabar Law Office is investigating claims on behalf of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) shareholders. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you are a current Kyverna (NASDAQ: KYTX) shareholder who purchased Kyverna shares on or near its February 8, 2024 IPO and still hold shares today, you may be able to seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/kyverna-shareholder-investigation/, contact Joshua Grabar at [email protected] or call us at 267-507-6085
Why? On February 8, 2024, Kyverna Therapeutics, Inc. (NASDAQ: KYTX) conducted its IPO, offering 14.5 million shares of its common stock to the public at a price of $22 per share for anticipated proceeds of over $296 million. Kyverna granted the Underwriter Defendants a 30-day option to purchase up to an additional 2.175 million shares of its common stock at the Offering Price, less underwriting discounts and commissions.
An underlying securities fraud class action complaint alleges that the registration statement and prospectus issued in connection with the Company's IPO misstated and/or omitted facts concerning the results of the Company's ongoing evaluation of KYV-101 in clinical trials. The Complaint further alleges that unbeknownst to investors, these representations were materially inaccurate, misleading, and/or incomplete because they did not disclose adverse data regarding one of Kyverna's trials, which adverse data was known to the Company at the time of the IPO.
What Can You Do Now? If you purchased Kyverna (NASDAQ: KYTX) on or near its February 8, 2024 IPO and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/kyverna-shareholder-investigation/, contact Joshua Grabar at [email protected]
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Electra Launches Debt-to-Equity Conversion and US$30 Million Financing with Lender Support to Advance North America's First Battery Grade Cobalt Refinery
TORONTO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) ('Electra' or the 'Company') has entered into a term sheet and transaction support agreement with its Lenders pursuant to which it will launch a debt-to-equity conversion that will reduce its convertible debt outstanding by 60% as part of a comprehensive financial restructuring (the 'Transaction'). In addition, the Company intends to launch a US$30 million financing (the 'Equity Financing'), which will include a US$10 million conditional commitment from the Lenders. Together, the Transaction and Equity Financing are designed to strengthen Electra's capital structure and provide the funding required to advance the commissioning of North America's first cobalt sulfate refinery. Key Terms Electra will convert approximately US$40 million of its outstanding Notes, plus accrued and unpaid interest, into equity at a price of US$0.60 per Common Share. This exchange will reduce total debt under the Notes to approximately US$27 million. The concurrent Equity Financing will consist of US$30 million of Units at a price of US$0.75 per Unit. Each Unit will consist of one Common Share and one Common Share purchase Warrant, with each Warrant exercisable for one Common Share for US$1.25 for a period of three (3) years from the date of issuance. The Equity Financing is expected to close in tandem with the Transaction. Current shareholders will have the right to purchase Units on the same terms as new investors, in proportion to their existing Common Share ownership. The remaining 40% of the Notes, plus accrued and unpaid interest, will be exchanged for a new term loan, maturing three years after completion of the Transaction. To support operations during the restructuring process, the Lenders are providing US$2 million in short-term bridge debt in the form of 90-day Bridge Notes. In return, the Lenders will gain the right to appoint one director to Electra's board of directors. The Bridge Notes will fund working capital needs leading up to a meeting of shareholders of the Company, regulatory approvals, and the closing of the Equity Financing, mitigating near-term default risk. Following completion of the Equity Financing and the Transaction, the Company intends to increase its Board size from five to seven members, with the Lenders having the right to appoint up to three Board members, relative to their ownership stake in the Company. 'Today marks a turning point for Electra,' said Trent Mell, CEO of Electra. 'By equitizing a majority of our debt and securing bridge financing, we are taking decisive action to create a sustainable capital structure and advance the steps required to complete the cobalt refinery, including arranging approximately US$30 million in additional capital. 'This restructuring is undeniably dilutive and difficult for existing shareholders, but it is both timely and necessary. We have rigorously explored the alternatives, including asset sales, mergers, and alternative financing structures, and none offered a preferable outcome. The Lenders have provided continued support since construction of Electra's refinery was paused due to post-COVID inflation and supply chain disruption, including through new debt funding, equity commitments, and multiple waivers or amendments to loan conditions. This transaction preserves the value of our core asset and provides the foundation for future growth. 'With shareholder approval, lender participation, and government support, we will soon be in a position to complete construction of North America's first cobalt sulfate refinery. This step, though challenging, is essential to strengthening the region's battery materials supply chain and enabling Electra to become a reliable partner for governments, OEMs, and commercial stakeholders.' 'By significantly reducing our debt and securing new capital, we are strengthening our financial foundation and aligning our funding with a clear, executable path to production,' commented Electra CFO, Marty Rendall. 'Together, this restructuring and financing, alongside other well-advanced financing initiatives, are expected to provide the capital needed to complete the refinery and create long-term value across our stakeholder base.' Electra's battery materials refinery is central to North America's efforts to onshore critical mineral supply chains, reduce reliance on China, and strengthen national and economic security. By advancing the continent's first cobalt sulfate refinery, Electra will provide a low-carbon, domestic source of a material essential for both electric vehicles and defense applications. The Company has already attracted support from multiple levels of government and from its Lender group, reinforcing broad-based confidence in the strategic importance of its project. Details of the Transaction Pursuant to the Transaction, holders of the Notes (the 'Lenders') will exchange 60% of the aggregate principal amount and the aggregate amount of all accrued and unpaid interest of the 8.99% senior secured convertible notes due February 13, 2028 and 12.0% senior secured convertible notes due November 12, 2027 (collectively, the 'Notes') for Common Shares at an exchange price of US$0.60 per Electra common share ('Common Share'), representing 60% of the aggregate value of the Notes, inclusive of principal and accrued and unpaid interest, reducing total debt under the Notes to approximately US$27 million. The Lenders will exchange the remaining 40% of the aggregate principal amount and the aggregate amount of all accrued and unpaid interest of the Notes for an equal aggregate principal amount of a new term loan. Interest on the new term loan will be payable in cash or in kind at the Company's election at a rate per annum of 8.99% if paid in cash or 11.125% if paid in kind. The new term loan will mature three (3) years from the date of the closing of the Transaction. To support operations during the Transaction process, the Lenders have agreed to purchase US$2 million aggregate principal amount of unsecured 90-day promissory notes ('Bridge Notes') to fund working capital (the 'Bridge Financing'). Interest on the Bridge Notes will be payable in cash at maturity at a rate of 12.00% per annum. Upon purchase of the Bridge Notes, the Lenders shall have the right to appoint a director to the board of directors of the Company (the 'Board'). The Company must redeem the Bridge Notes at a redemption price equal to 100% of the aggregate principal amount of the Bridge Notes, plus all accrued and unpaid interest thereon, in connection with the completion of the Transaction. The Transaction remains subject to the satisfaction of a number of conditions precedent, including receipt of regulatory approvals (including the TSX Venture Exchange (the 'TSXV')) and shareholder approval, as it is expected that the Transaction will result in the creation of one or more 'control persons,' as defined under applicable securities law, and the negotiation and execution of definitive documentation for the Transaction on terms acceptable to the Company and the Lenders. In connection with the Transaction, the Company will hold a special meeting of shareholders, expected to be held in October 2025, where shareholders will, among other things, be asked to approve a consolidation of the Company's shares at a ratio to be determined by the Board. The Transaction is expected to close shortly thereafter. All components of the Transaction are expected to occur concurrently, other than the funding of the Bridge Notes which is expected to occur in the coming days. Details of the Equity Financing The Equity Financing will consist of units ("Units') raising US$30 million at a price of US$0.75 per Unit. Each Unit will consist of one Common Share and one Warrant, with each Warrant exercisable for one Common Share for US$1.25 for a period of three (3) years from the date of issuance. The Equity Financing will include a US$10 million commitment from the Lenders, subject to the satisfaction of certain conditions. It is anticipated that the net proceeds from the Equity Financing will be used to fund the completion and ramp-up of the Company's cobalt refinery in Temiskaming Shores, Ontario, to repay the Bridge Notes to be issued to the Lenders, and for general corporate and working capital purposes. The Equity Financing will close in tandem with the Transaction. In the event the gross proceeds from the Equity Financing are greater than US$34.5 million the Company will allocate the excess to repayment of the Notes at a purchase price of par plus accrued and unpaid interest. The Company will issue a further news release once the structure for the Equity Financing has been finalized. TSXV Waiver Neither the equitization price of the Notes, nor the offering price of the Units comply with the TSXV minimum pricing requirements under TSXV Policy 4.1 – Private Placements which mandate that the offering price of securities issued under an equity offering must not be less than the Discounted Market Price (as defined in the policies of the TSXV) for the Common Shares. The Company has therefore applied for a waiver in respect of the pricing requirements, however, there is no assurance that such a waiver will be granted. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the 'United States' or to 'U.S. Persons' (as such terms are defined in Regulation S under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act')). The securities have not been and will not be registered under the U.S. Securities Act, or any U.S. state securities laws, and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. All securities offered and sold pursuant to the Equity Financing in the United States or to U.S. Persons will be offered and sold in reliance on the exemption from the registration requirements of the U.S. Securities Act provided by Rule 506(c) of Regulation D under the U.S. Securities Act, or another available exemption, and similar exemptions under applicable U.S. state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About Electra Battery Materials Electra is a leader in advancing North America's critical minerals supply chain for lithium-ion batteries. Currently focused on developing North America's only cobalt sulfate refinery, Electra is executing a phased strategy to onshore critical minerals refining and reduce reliance on foreign supply chains. In addition to establishing the cobalt sulfate refinery, Electra's strategy includes nickel refining and battery recycling. Growth projects include integrating black mass recycling at its existing refining complex, evaluating opportunities for cobalt production in Bécancour, Quebec, and exploring nickel sulfate production potential in North America. For more information, please visit ContactHeather SmilesVice President, Investor Relations & Corporate Development Electra Battery Materialsinfo@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements and forward-looking information (together, 'forward-looking statements') within the meaning of applicable securities laws and the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, are forward-looking statements and include, but are not limited to, statements regarding the closing of the Transaction and anticipated timing thereof, the expected reduction in the Company's outstanding debt and the impact on its capital structure, the expected appointment of directors to the Board by the Lenders, the granting of a waiver from the TSXV pricing requirements, and receipt of required regulator and shareholder approvals, the creation of one or more control persons under applicable securities laws, the anticipated government funding, the Company's continued eligibility for U.S. Department of Defense grants, the expected ramp-up and commissioning of the cobalt sulfate refinery, Electra's strategic role in reshoring North America's battery materials supply chain, and the Company's future growth plans, including nickel refining and battery recycling. Generally, forward-looking statements can be identified by the use of terminology such as 'plans', 'expects', 'will,' 'estimates', 'intends', 'anticipates', 'believes' or variations of such words, or statements that certain actions, events or results 'may', 'could', 'would', 'will,' 'might', 'occur' or 'be achieved'. Forward-looking statements are based on certain assumptions, and involve risks, uncertainties and other factors that could cause actual results, performance, and opportunities to differ materially from those implied by such forward-looking statements. Among the bases for assumptions with respect to the potential for additional government funding are discussions and indications of support from government actors based on certain milestones being achieved. Factors that could cause actual results to differ materially from these forward-looking statements are set forth in the management discussion and analysis and other disclosures of risk factors for Electra Battery Materials Corporation, filed on SEDAR+ at and on EDGAR at Other factors that could lead actual results to differ materially include failure to obtain required approvals or satisfy closing conditions, changes in government policy or funding commitments, delays in construction or commissioning of the refinery, inability to complete the Transaction or Equity Financing on the proposed terms and general economic, market, and geopolitical conditions. Although the Company believes that the information and assumptions used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed times frames or at all. Except where required by applicable law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Business Wire
17 minutes ago
- Business Wire
Intentsify Makes the Inc. 5000 Fastest-Growing Private Companies in America for Third Consecutive Year
WESTWOOD, Mass.--(BUSINESS WIRE)--Intentsify, the leading provider of AI-generated persona-level intent data and signal-based marketing solutions, today announced that it has been named to the 2025 Inc. 5000 list of the fastest-growing private companies in America. Ranking No. 3462, this marks Intentsify's third appearance on the prestigious list, underscoring the company's continued rapid growth and market leadership in the B2B marketing technology sector. The Inc. 5000 list provides a data-driven look at the most successful companies within the economy's most dynamic segment—its independent, entrepreneurial businesses. Intentsify's inclusion underscores its position as a market leader, despite turbulent economic headwinds prohibiting growth for many competitor brands. Key achievements that contributed to Intentsify's growth and Inc. 5000 recognition: It's strategic acquisition of Five by Five, the industry's largest data cooperative and identity graph. Launch of persona- and buying group-level intent data that gives B2B teams the data they need to execute sophisticated GTM strategies. Recognition as a Leader and #1 Strength of Offering in The Forrester Wave™: B2B Intent Data Providers Q1. Launch of Audience Solutions that expands activation offerings. 'Our continued presence on the Inc. 5000 list is a direct reflection of our team's unwavering commitment to innovation," said Marc Laplante, CEO & Co-Founder of Intentsify. "In a dynamic and crowded market, we've remained focused on delivering groundbreaking solutions, from our strategic acquisition of Five by Five to the launch of Buying Group Intent. This recognition underscores our position as a leader in B2B marketing technology and validates the impact our product has on helping our clients accelerate revenue.' In addition to the nationwide ranking, Intentsify was also recognized as 85 th fastest-growing company in the Boston metro area and 337 th fastest-growing company in the Business Products and Services industry. About Intentsify Intentsify's AI-powered platform empowers teams to turn buying signals into pipeline with customized advertising and lead generation programs. Combining an unrivaled portfolio of data sources and an industry-leading media ecosystem, Intentsify enables full-funnel marketing programs for revenue acceleration. Learn more at
Business Wire
17 minutes ago
- Business Wire
Viant and AdTegral Partner to Activate SMB Agencies and Brands
IRVINE, Calif. & DALLAS--(BUSINESS WIRE)-- Viant Technology Inc. (NASDAQ: DSP), a leader in CTV and AI-powered programmatic advertising, today announced a strategic partnership with AdTegral, a programmatic media solutions provider known for its data-driven, hands-on approach to campaign execution and measurement. As Viant's debut activation partner, AdTegral will enable agencies and brands to access and activate campaigns on Viant's award-winning demand-side platform (DSP) through a first-of-its-kind co-managed, performance-optimized model with no spend minimum levels to access. This partnership marks the first certified integration of the Viant DSP into a third-party platform, unlocking expanded access to Viant's technology, scale, and performance for small and mid-sized advertisers. 'Our collaboration with AdTegral supports Viant's mission to deliver smarter, scalable, outcomes to small and mid-market advertisers,' said Josh Hare, EVP of Sales at Viant. Share Viant is AdTegral's exclusive DSP activation partner, selected for its Connected TV (CTV) leadership, AI-powered platform, and advanced reporting capabilities which help brands optimize performance across the entire customer journey. This partnership is designed to streamline media buying and democratize programmatic access for advertisers who may lack large monthly media budgets but still seek to leverage Viant's powerful DSP— all while benefiting from expert-led campaign build, launch, optimization and performance measurement. 'Our collaboration with AdTegral supports Viant's mission to deliver smarter, scalable, outcomes to small and mid-market advertisers,' said Josh Hare, EVP of Sales at Viant. 'By combining Viant's advanced platform with AdTegral's hands-on activation model, advertisers gain a powerful solution that drives efficiency, precision and measurable impact.' AdTegral's certified programmatic team, built with skilled planners and traders from the agency Aletheia, will oversee campaign lifecycle management—helping to ensure a seamless client experience from onboarding to optimization, with a clear pathway to transition into Viant's DSP. The co-managed model provides advertisers with a cost-effective entry into Viant's platform, which supports advanced identity resolution, real-time measurement, and omnichannel targeting across Connected TV (CTV), desktop, mobile, audio, and DOOH. 'Viant's platform—powered by a robust identity graph, AI-driven tools and advanced reporting solutions—represents the future of programmatic advertising,' said Patrick Derdeyn, SVP of Business Development at AdTegral. 'We're proud to partner exclusively with the Viant DSP to bring these capabilities to advertisers seeking immediate impact and long-term strategic advantage through expert-led media execution.' The partnership will deliver value across key verticals, including retail, healthcare and CPG, where programmatic performance, transparency and measurement are critical. With this collaboration, Viant and AdTegral set a new standard for co-managed DSP efficiency and performance. About Viant Viant Technology Inc. (NASDAQ: DSP) is a leader in CTV and AI-powered programmatic advertising, dedicated to driving innovation in digital marketing. Viant's omnichannel platform built for CTV allows marketers to plan, execute and measure their campaigns with unmatched precision and efficiency. With the launch of ViantAI, Viant is building the future of fully autonomous advertising solutions, empowering advertisers to achieve their boldest goals. Viant was recently awarded Best AI-Powered Advertising Solution and Best Demand-Side Platform by MarTech Breakthrough, Great Place to Work® certification and received the Business Intelligence Group's AI Excellence Award. Learn more at About AdTegral AdTegral delivers engineered programmatic solutions committed to trust, transparency, and reliability with a data-driven hands-on approach to programmatic media buying and measurement. Our experts ensure every campaign is optimized for maximum efficiency, precision, and impact. We leverage historical performance data, trend analysis, and predictive modeling to identify what's working—and what's not—allowing us to pivot swiftly and continuously improve campaign efficiency. Learn more at
